news
METIS meets primary endpoint
The phase 3 METIS clinical trial demonstrated a statistically significant improvement in time to intracranial progression for patients treated with Tumor Treating Fields therapy and supportive care compared to supportive care alone in the treatment of patients with brain metastases from non-small cell lung cancer following stereotactic radiosurgery.
learn morenews
FDA PMA application update
Our Premarket Approval application seeking approval for the use of Tumor Treating Fields therapy together with standard systemic therapies for the treatment of non-small cell lung cancer, following progression on or after platinum-based therapy, has been accepted for filing by the U.S. FDA.
learn morenews
TRIDENT enrollment complete
The final patient has been enrolled in the global phase 3 TRIDENT clinical trial evaluating the safety and efficacy of initiating Optune Gio® concurrent with radiation therapy and temozolomide for the treatment of adult patients with newly diagnosed glioblastoma.
learn moreThe phase 3 METIS clinical trial in brain metastases from non-small cell lung cancer following stereotactic radiosurgery met its primary endpoint. https://www.novocure.com/metis-phase-3-clinical-trial-met-primary-endpoint-demonstrating-a-statistically-significant-extension-in-time-to-intracranial-progression-for-patients-with-brain-metastases-from-non-small-cell-lung-c/ #oncology #clinicaltrials
What a week at the European Lung Cancer Congress! Our team appreciated the chance to exchange insights with cancer specialists and discuss the principles of our innovative Tumor Treating Fields (TTFields) therapy.
Learn more about us: http://www.novocure.com/about-us
#ELCC24 #ESMO #IASLC
Meet Christian Kruhl, MD. He is at the European Lung Cancer Congress this week in Prague.
Visit Christian and our team at Stand 2E2 in the Congress Hall Foyer to learn more about our innovative Tumor Treating Fields therapy.
#ELCC24 #TTFields
https://www.tumortreatingfieldstherapy.com
We are excited to participate in #ELCC24 this week in Prague. We look forward to learning from oncology experts and raising awareness of our innovative Tumor Treating Fields (TTFields) therapy.
Learn more about #TTFields: https://www.tumortreatingfieldstherapy.com/
#WeAreNovocure #ESMO #IASLC
Patients, caregivers and their families are at the heart of our mission. That is why we are proud to support the “Empowering Caregivers” webinar from @theABTA. If you are a #caregiver or know one, learn more. http://bit.ly/MarchPFM2024 #patientforward #BTSM
A late breaking abstract with results of an exploratory subgroup analysis of the phase 3 ENGOT-ov50 / GOG-3029 / INNOVATE-3 clinical trial was selected as a best oral presentation and shared yesterday at the @ESGO_society 2024 Congress. #ESGO2024 https://www.novocure.com/innovate-3-late-breaking-abstract-selected-as-a-best-oral-presentation-at-esgo/